Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | KAT8 | Q9H7Z6 | 7/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12430722 | 0.90 | KMT2A (0.49) | MAPTALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL12857602 | 0.82 | KDM4E (0.53) | MAPTALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL12430715 | 0.79 | KMT2A (0.48) | MAPTALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL14599445 | 0.78 | KMT2A (0.45) | MAPTALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL14599442 | 0.78 | LMNA (0.49) | MAPTALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL12430720 | 0.78 | KMT2A (0.53) | MAPTALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL12510605 | 0.77 | MAPT (0.49) | MAPTALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL14599447 | 0.75 | KMT2A (0.47) | MAPTALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL1304495 | 0.74 | KAT8 (0.55) | MAPTALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL12104822 | 0.74 | KAT8 (0.55) | MAPTALDH1A1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977366-B2 | Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation | CORNELL RESEARCH FOUNDATION, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20070021448-A1 | Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-25 | — | — | US | disclosed |
| US-20070021448-A1 | Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021448-A1 | Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation | MPO, MMP8, SERPINB1 | MAPT 4440/4885ALDH1A1 705/4885SMN1; SMN2 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.